（记者 张海妮） 截至发稿，华兰股份市值为65亿元。 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 每经AI快讯，华兰股份（SZ 301093，收盘价：39.49元）10月22日晚间发布三季度业绩公告称，2025年 前三季度营收约4.41亿元，同比增加4.36%；归属于上市公司股东的净利润约5332万元，同比增加 2.06%；基本每股收益0.325元，同比增加4.17%。 ...

具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的 《2025 年第三季度报告》。 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第七次会议通知于 2025 年 10 月 15 日以邮件、电话等方式向各位董 事发出，会议于 2025 年 10 月 21 日以现场会议结合通讯形式召开。本次会议由 公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议的 董事 9 人，其中肖锋先生、崔珂女士、姚茗芳女士、单体超先生、陈岗先生、 刘力先生、侯绪超先生以通讯表决方式出席本次董事会会议，公司高级管理人 员列席了会议。本次会议的召集、召开及表决符合《公司法》等有关法律、法 规、规范性文件和《公司章程》的规定，会议合法、有效。 二、 董事会会议审议情况 1、会议以 9 票同意、0 票反对、0 票弃权，审议通过了《关于<2025 年第 三季度报告>的议案》。 证券代码：301093 证券简称：华兰 ...

Core Insights - Hualan Co., Ltd. reported a revenue of 441 million yuan for the first three quarters of 2025, representing a year-on-year growth of 4.36% [1] - The net profit attributable to shareholders of the listed company was 53.316 million yuan, showing a year-on-year increase of 2.06% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 40.826 million yuan, reflecting a year-on-year growth of 13.66% [1] - The basic earnings per share stood at 0.325 yuan [1]

Core Viewpoint - Hualan Co., Ltd. announced the convening of its sixth board meeting to review the third quarter report for 2025, indicating ongoing corporate governance and financial oversight [1] Company Summary - Hualan Co., Ltd. reported that for the first half of 2025, 99.07% of its revenue came from the pharmaceutical manufacturing sector, while other businesses contributed only 0.93% [1] - As of the report, Hualan Co., Ltd. has a market capitalization of 6.5 billion yuan [1]

Core Viewpoint - Hualan Co., Ltd. reported a revenue of 441 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 4.36% [1] - The net profit attributable to shareholders reached 53.32 million yuan, marking a year-on-year increase of 2.06% [1] - The net profit after deducting non-recurring gains and losses was 40.83 million yuan, showing a year-on-year growth of 13.66% [1] - Basic earnings per share stood at 0.325 yuan [1] Financial Performance - Revenue for the first three quarters: 441 million yuan, up 4.36% year-on-year [1] - Net profit attributable to shareholders: 53.32 million yuan, up 2.06% year-on-year [1] - Net profit after non-recurring items: 40.83 million yuan, up 13.66% year-on-year [1] - Basic earnings per share: 0.325 yuan [1]

Core Insights - The company reported a third-quarter revenue of 132 million yuan, representing a year-on-year decline of 4.72% [1] - The net profit for the third quarter was 9.58 million yuan, down 37.20% year-on-year [1] - For the first three quarters, the company achieved a revenue of 441 million yuan, which is a year-on-year increase of 4.36% [1] - The net profit for the first three quarters was 53.32 million yuan, reflecting a year-on-year growth of 2.06% [1] Financial Performance - Third-quarter revenue: 132 million yuan, down 4.72% year-on-year [1] - Third-quarter net profit: 9.58 million yuan, down 37.20% year-on-year [1] - Year-to-date revenue (first three quarters): 441 million yuan, up 4.36% year-on-year [1] - Year-to-date net profit (first three quarters): 53.32 million yuan, up 2.06% year-on-year [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 132,482,970.99, a decrease of 4.72% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 9,583,905.64, down 37.20% year-on-year[4] - The basic earnings per share (EPS) was CNY 0.0587, reflecting a decline of 35.92% compared to the previous year[4] - Total operating revenue for the current period reached ¥441,244,733.57, an increase of 4.3% compared to ¥422,796,240.46 in the previous period[24] - Net profit for the current period was ¥53,228,184.49, slightly higher than ¥52,237,238.79 from the previous period, indicating a growth of 1.9%[25] - The total comprehensive income for the period was CNY 53,203,987.60, compared to CNY 52,237,238.79 in the previous period, reflecting an increase[26] - Basic and diluted earnings per share increased to CNY 0.325 from CNY 0.312, representing a growth of 4.2%[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,517,621,152.73, an increase of 0.51% from the end of the previous year[4] - The company's total assets increased to ¥2,517,621,152.73 from ¥2,504,747,738.80, marking a growth of 0.5%[22] - Current assets totaled ¥1,696,410,418.59, a marginal increase from ¥1,694,546,494.58, showing a growth of 0.1%[21] - The total liabilities increased to ¥339,410,297.54 from ¥255,985,703.16, reflecting a rise of 32.5%[22] - The company's equity attributable to shareholders decreased to ¥2,173,815,374.04 from ¥2,245,764,811.04, a decline of 3.2%[23] Cash Flow - Cash flow from operating activities showed a net decrease of 38.84%, totaling CNY 76,392,286.01[4] - Cash flow from operating activities generated a net amount of CNY 76,392,286.01, down from CNY 124,903,079.59 in the previous period, indicating a decline of 38.7%[26] - Cash inflow from investment activities totaled CNY 2,749,626,741.19, compared to CNY 1,868,199,767.22 in the previous period, marking an increase of 47%[27] - The net cash flow from investment activities was CNY 81,506,737.58, up from CNY 49,966,552.03, showing a growth of 63.2%[27] - Cash flow from financing activities resulted in a net outflow of CNY 5,302,493.58, an improvement from a net outflow of CNY 304,706,045.98 in the previous period[27] - The ending balance of cash and cash equivalents increased to CNY 530,608,277.75 from CNY 278,556,876.99, reflecting a growth of 90.5%[27] Investments and Income - Investment income decreased by 63.73% to CNY 4,837,039.94 due to reduced returns from cash management products[11] - The company’s cash management income increased significantly, contributing to a fair value change gain of CNY 8,603,831.56, up 121.91% year-on-year[11] - The company received CNY 2,727,000,000.00 from the recovery of investments, significantly higher than CNY 1,822,960,000.00 in the previous period, indicating a growth of 49.7%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,278, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., holds 22.39% of shares, totaling 36,764,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Ruizhong Life Insurance Co., Ltd., holding 16.38% or 26,901,579 shares[14] - The company has a total of 2,975,699 shares held in its repurchase special securities account, accounting for 1.81% of the total share capital[16] - The company plans to unlock shares held by executives and other stakeholders according to the established schedule, with significant amounts set for release in May 2025[18] Operating Costs and Expenses - Total operating costs amounted to ¥393,422,388.46, up from ¥380,153,962.71, reflecting a rise of 3.3%[24] - Research and development expenses for the current period were ¥29,541,151.81, compared to ¥28,885,335.31 in the previous period, indicating an increase of 2.3%[24] - Cash paid for dividends, profits, or interest decreased by 67.39% to $25,312,311.97, reflecting a reduction in cash dividends distributed[13] - Cash paid for other financing activities decreased by 52.96% to $108,243,481.61, due to a reduction in the implementation of share repurchases[13]

Market Performance - The medical device sector increased by 1.01% on October 21, with Botao Bio leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers - Botao Bio (688767) closed at 43.39, up 8.12% with a trading volume of 50,200 shares and a transaction value of 216 million [1] - Xiangsheng Medical (688358) closed at 34.93, up 6.62% with a trading volume of 45,600 shares and a transaction value of 157 million [1] - Hualan Biological (301093) closed at 39.30, up 6.53% with a trading volume of 57,500 shares and a transaction value of 223 million [1] Top Losers - Jinhao Medical (920925) closed at 31.85, down 2.24% with a trading volume of 11,900 shares and a transaction value of 37.83 million [2] - Toukeng Life (300642) closed at 26.75, down 2.01% with a trading volume of 162,300 shares and a transaction value of 44.4 million [2] - Maillande (688273) closed at 40.48, down 1.99% with a trading volume of 22,300 shares and a transaction value of 90.15 million [2] Capital Flow - The medical device sector experienced a net outflow of 229 million from institutional investors and 168 million from retail investors, while retail investors saw a net inflow of 397 million [2][3] - Notable capital inflows included Xinhua Medical with a net inflow of 24.93 million from institutional investors [3] - Hualan Biological had a net inflow of 20.37 million from institutional investors, despite a net outflow from retail investors [3]

证券代码：301093 证券简称：华兰股份 公告编号：2025-104 江苏华兰药用新材料股份有限公司 关于 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 持有人会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）2025 年员工持股 计划第一次持有人会议（以下简称"本次会议"）于 2025 年 10 月 17 日以通讯 方式召开。 本次会议由公司副总经理、董事会秘书刘雪女士召集和主持，会议出席持 有人 225 人，代表 2025 年员工持股计划持有人持有股份数 2,783,132 股，占 2025 年员工持股计划有表决权股份总数的 97.68%。本次会议的通知、召开和表 决程序符合相关法律法规及公司 2025 年员工持股计划的有关规定，会议所作决 议合法有效。 二、 持有人会议审议情况 （一）审议通过《关于设立公司 2025 年员工持股计划管理委员会的议案》 为保证公司 2025 年员工持股计划的顺利实施，保障持有人的合法权益，根 据公司《2025 年员工持股计划（草案）》《2025 年员 ...

Group 1 - The core point of the news is that Hualan Co., Ltd. experienced a decline of 5.14% in its stock price, reaching 34.51 CNY per share, with a total market capitalization of 5.667 billion CNY [1] - Hualan Co., Ltd. is primarily engaged in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - From the perspective of major fund holdings, one fund under Dacheng Fund has a significant position in Hualan Co., Ltd., with 620,000 shares held, accounting for 3.29% of the fund's net value [2] - The Dacheng Growth Mixed Fund (160926) has reported a floating loss of approximately 1.1594 million CNY due to the decline in Hualan's stock price [2] - The fund has achieved a year-to-date return of 25.68% and a one-year return of 27.96%, ranking 3506 out of 8160 and 3478 out of 8021 respectively in its category [2]